Scan to get started on Sahi
Rethink Trading
A new age Broking platform with in-house Sahi charts, real-time AI intelligence, and flat ₹10 per order brokerage.
4.5 ★ | 38K+ Ratings | IFTA Startup of the year 2025 | 8M+ downloads
Built for single-screen high performance acrossOptions Buying
Options Buying
Options Buying
Introducing the new & improved Sahi Scalper 2.0
Analyse & execute on a multi-chart layout. Watch the Index and Option Charts, Call & Put, Option Chain, simultaneously without moving an eye from your P&L.
Seamless Options Trading with Powerful Tools
Stay nimble and execute faster than ever before – no matter the screen size.
Trade from Charts, at Sahi Speed
Sahi’s powerful charts are built in-house & give you full control over your trades. Manage risk, optimize entries and exits, and never miss a movement – all without leaving your chart.
Real-Time market intelligence with Sahi AI
Tracks trends, identifies breakouts, highlights the hottest stocks
Analyse, Trade Option Strategies With Confidence
Create strategies that work for you. More control, better results.
Personalized Trading:
Tailor Your Space and Strategy
Personalize your homepage layout to match your trading style. Set up your workspace the way you want it, with just the tools you need.
High Performance Trading
at Incredible Value
Pay only ₹10 per executed order.
Latest news
HEG Advanced Materials Q2 Consolidated Net Profit Rises To ₹300 Crore On ₹430 Crore Revenue
- Consolidated revenue from operations for Q2 FY27 reached ₹429.94 crore, up from ₹175.94 crore in Q2 FY26. - Consolidated EBITDA for the quarter stood at ₹312.78 crore. - Board approved a ₹1,606 crore capex project to expand anode plant capacity from 20,000 MT to 44,000 MT.
Parag Milk Foods Q2 EBITDA Rises To ₹993 Million With Margin Expanding To 8%
Parag Milk Foods delivered robust earnings performance for Q2, growing EBITDA by ≈39.39% YoY to ₹99.3 crore. Operating margins improved by 93 basis points YoY to 8%, driven by volume growth and operational leverage across core value-added dairy categories.
Metropolis Healthcare Signals Margin Expansion Outlook Driven By Planned Price Increases
Metropolis Healthcare achieved consolidated Q2 FY27 revenue of ₹497 crore with an EBITDA margin of 27.2%, reflecting an expansion of 180 basis points year-on-year. Official management guidance targets sustained EBITDA margins between 27% and 28%, anchored by network utilization and operational leverage.
